3. The drug companies implemented price monopoly, which led to a sharp rise in drug prices, and were fined 2.6 million yuan by the national development and Reform Commission

Source: NDRC price supervision and inspection and Antimonopoly Bureau sub station on May 27, 2016, NDRC issued notice on special inspection of drug price nationwide (fgyj [2016] No 1101) API is the key inspection object Yesterday, the punishment result of NDRC came out, and three companies were severely punished more than 2.6 million Although the price after the final increase is only 10%, the price is still very low, but the price increase is illegal and can only be fined The national development and Reform Commission recently imposed a total fine of more than 2.6 million yuan on three companies including Huazhong pharmaceutical, Shandong Xinyi and Changzhou No Estazolam is a kind of second-class psychoactive drug strictly controlled by the state Estazolam tablet belongs to the nervous system drug in the national basic drug catalog and is listed in the national low-cost drug catalog China strictly controls the access and production of class II psychotropic drug APIs There are only four enterprises in China that have obtained the approval documents for the production of estazolam APIs, and only four enterprises in China, Shandong Xinyi and Changzhou, which are also the manufacturers of estazolam tablets The survey found that after the introduction of the low-cost drug policy in 2014, three enterprises reached and implemented the monopoly agreement of boycott in the drug market of estazolam through meetings, meetings, phone calls, SMS, e-mail, etc., and reached and implemented the monopoly agreement of fixing or changing the commodity price in the drug market of estazolam From September to October 2014, the parties held a meeting in Zhengzhou, Henan Province, to discuss the arrangement of eszolam APIs and tablets At last, the parties reached the following consensus: first, the drug substance of estazolam produced by each enterprise is only used for the production of tablets by the company and will not be exported; second, they have a tacit agreement on the collective price increase of estazolam tablets Since December 2014, three enterprises have gradually increased the price of estazolam tablets by issuing price adjustment letters Huazhong pharmaceutical and Shandong Xinyi have communicated with each other on price adjustment information through meetings, phone calls, SMS and other forms for many times From 2013 to 2014, the parties supplied APIs to 16 downstream tablet manufacturers, according to the API sales data from which the tablets increased to 1 gross / 1 tablet After October 2014, the parties successively stopped normal supply to the outside world, and the APIs produced were for their own use only Most tablet manufacturers were forced to stop production due to lack of APIs The obtained tablet sales data show that since December 2014, the prices of estazolam tablets sold by three enterprises have increased substantially, and the timing of price increase is highly consistent, which proves that the price monopoly agreement of joint price increase has been substantially implemented Taking aszolam tablets of 1mg * 20 specifications produced by three enterprises as an example, from 2015 to now, the ex factory price of China pharmaceutical industry has increased more than three times, Shandong Xinyi has increased nearly two times, Changzhou No.4 pharmaceutical has increased 1.6 times, and the ex factory price of aszolam tablets of three enterprises has increased to about 1 Mao / tablet Huazhong pharmaceutical, Shandong Xinyi and Changzhou siyao, as independent market entities of production and sales of estazolam APIs and tablets, belong to the operators with competitive relationship in the market of estazolam APIs and the market of estazolam tablets The monopoly agreement reached and implemented by the parties involved in the boycott of estazolam APIs forced other tablet manufacturers to withdraw from the market due to the lack of key inputs, which seriously excluded and restricted the competition in the tablet market, and also cleared the obstacles to the implementation of joint price increase in the tablet market The monopoly agreement on increasing the price of estazolam tablets reached and implemented by the parties directly led to the sharp increase in the price of estazolam tablets since 2015, increased the burden of drug costs for the majority of patients and damaged the interests of consumers Under the joint effect of the two monopoly agreements, the total market supply of estazolam tablets decreased, and the accessibility of patients was affected According to the nature, degree and duration of the monopoly, the different roles of the parties in the monopoly agreement and the degree of cooperation with the investigation, the national development and Reform Commission ordered the parties to stop implementing the monopoly agreement immediately according to law, and the total penalty was 2603823 yuan Among them, Shandong Xinyi, who played a leading role in the conclusion and implementation of the monopoly agreement, was fined 7% of the sales of estazolam tablets in 2015, totaling 1571829 yuan; Shandong Xinyi, who participated in the monopoly agreement and cooperated with the administrative organ in the investigation of illegal acts and performed meritorious deeds, was punished in 2015 A fine of 2.5% of the annual sales of estazolam tablets is RMB 547563; a fine of 3% of the sales of estazolam tablets in 2015 is imposed on the follower of the monopoly agreement, the four drugs in Changzhou, which are less illegal and can be actively rectified, totaling RMB 484431 The national development and Reform Commission has recently issued the notice on special inspection of drug prices nationwide (fgyj [2016] No 1101), focusing on the inspection of APIs and drug varieties with abnormal price fluctuations, focusing on solving the problems strongly reflected by the masses and enterprises, and earnestly maintaining the medicine Fair market competition order, protect the legitimate rights and interests of patients All sectors of society are welcome to participate in the regulation of drug prices through the 12358 price supervision platform Attachment: seven key points of strict price inspection by the national development and Reform Commission: (1) the behaviors of the production and operation enterprises of APIs and drugs to reach and implement monopoly agreements, and the behaviors of the industry associations to organize the production and operation enterprises to reach and implement monopoly agreements （2） Abuse of market dominant position and unfair high price sales of APIs and pharmaceuticals by API and pharmaceutical production and marketing enterprises; (3) price frauds such as fictitious original price and misleading price labeling by social retail enterprises; (4) medical institutions' failure to implement the policy of zero difference and markup rate of government priced pharmaceuticals （5） The behavior of the government pricing drugs to break through the highest ex factory (retail) price sales stipulated by the government; (6) the behavior of not implementing the system of clearly marked price and price publicity according to the regulations; (7) other behaviors in violation of the price law and anti-monopoly law